Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q) has officially received approval from the Canadian Patent Office for a new patent titled "Process for Preparation of Biologically Active Copolymer," which is set to remain valid until 2041. This represents a valuable addition to Recce's global patent portfolio, providing exclusive marketing and manufacturing rights in Canada until at least January 2041.

Recce Pharmaceuticals, expressed appreciation for the Canadian government's acknowledgment of the potential of Recce's New Class of Anti-infectives. The granted patent covers RECCE® 327 (R327) and RECCE® 529 (R529) and includes claims related to the preparation of RECCE® anti-infectives, their application in treating various diseases, and validation from studies across multiple infections such as burn wounds, urinary tract infections, gonorrhea, influenza, and SARS-CoV-2.

The patent encompasses administration methods, including oral, inhalation, transdermal, or injection delivery, and various application forms such as aerosols, gels, topical foams, or ointments. Notably, this marks Recce's first wholly-owned patent granted in Canada, with additional Patent Cooperation Treaty Country (PCT) submissions at different stages of review.

In July 2023, Recce Pharmaceuticals received an AUD $98,428 R&D Rebate from the Canadian Government under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program, aimed at encouraging businesses to conduct R&D in Canada.

The patent specifies bacterial pathogens covered in Family Four, including Proteus species, Serratia species, Pseudomonas aeruginosa, and others. Additionally, it addresses viral pathogens such as herpes, HIV, cytomegalovirus, influenza, and SARS-CoV-2.

Recce Pharmaceuticals is at the forefront of developing a New Class of Synthetic Anti-Infectives to combat antibiotic-resistant superbugs and emerging viral pathogens. The company's pipeline includes RECCE® 327 for serious bacterial infections, RECCE® 435 for oral bacterial infections, and RECCE® 529 for viral infections. RECCE® 327 has received Qualified Infectious Disease Product designation from the FDA, positioning it for Fast Track Designation and 10 years of market exclusivity post-approval. The company wholly owns its automated manufacturing facility, supporting ongoing clinical trials as it seeks to address unmet medical needs with its innovative technologies.

 

Source: globenewswire.com

Report Abuse